ASSESSING THE EFFICACY OF NITAZOXANIDE IN TREATMENT OF CRYPTOSPORIDIOSIS USING PCR EXAMINATION
- PMID: 30230765
ASSESSING THE EFFICACY OF NITAZOXANIDE IN TREATMENT OF CRYPTOSPORIDIOSIS USING PCR EXAMINATION
Abstract
Cryptosporidiosis is a gastrointestinal disease of humans and other animals, caused by the genus Cryptosporidium spp. It causes persistent diarrhea and malnutrition and is associated with increased mortality. This study aimed to assess the efficacy of nitazoxanide (NTZ) on clearing the oocysts of C. parvum among infected children using both parasitological and PCR techniques.120 children (1-12y) shedding Cryptosporidium oocysts in their stools were enrolled in the study. They were classified on the basis of the immune status into immunocompetent (ICT) and immunocompromised (ICZ) groups. Each group were subdivided into two groups one of them received'NTZ, and the other received placebo. The efficacy of nitazoxanide was assessed clinically, parasitologically and by nested-PCR technique. At the end of 1st week of treatment, 80% of ICT/ NTZ group and 40% of ICT/ placebo group were free by PCR and 83.3% & 20% respectively were microscopically free. While at the end of 4th week, 93.3% of ICT/NTZ group and 43.3% of ICT/ placebo group were free by PCR and 96.7% & 26.7% respectively were microscopically free. Among the ICZ group, diarrhea was resolved in most patients receiving NTZ within 21 to 28 days of treatment initiation While, it resolved in the ICT group receiving NTZ in most patients within 3 to 5 days of treatment initiation.
Similar articles
-
Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves.J Dairy Sci. 2009 Apr;92(4):1643-8. doi: 10.3168/jds.2008-1474. J Dairy Sci. 2009. PMID: 19307646 Clinical Trial.
-
Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial.Lancet. 2002 Nov 2;360(9343):1375-80. doi: 10.1016/S0140-6736(02)11401-2. Lancet. 2002. PMID: 12423984 Clinical Trial.
-
Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia.Int J Infect Dis. 2013 Aug;17(8):e593-600. doi: 10.1016/j.ijid.2012.11.023. Epub 2013 Jan 3. Int J Infect Dis. 2013. PMID: 23291034
-
Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review.BMC Infect Dis. 2020 Mar 30;20(1):257. doi: 10.1186/s12879-020-04988-7. BMC Infect Dis. 2020. PMID: 32228484 Free PMC article. Review.
-
Drug treatment and novel drug target against Cryptosporidium.Parasite. 2008 Sep;15(3):275-81. doi: 10.1051/parasite/2008153275. Parasite. 2008. PMID: 18814694 Review.
Cited by
-
Therapeutic potential of platelet rich plasma against experimental Cryptosporidium parvum infection: in vivo study in immunosuppressed mice.J Parasit Dis. 2024 Dec;48(4):849-859. doi: 10.1007/s12639-024-01713-y. Epub 2024 Aug 7. J Parasit Dis. 2024. PMID: 39493467
-
Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions.Parasite. 2025;32:7. doi: 10.1051/parasite/2025001. Epub 2025 Feb 4. Parasite. 2025. PMID: 39902829 Free PMC article. Review.
-
Efficacy of nitazoxanide, ivermectin and albendazole in treatment of cryptosporidiosis in immunosuppressed mice.J Parasit Dis. 2025 Jun;49(2):343-350. doi: 10.1007/s12639-024-01751-6. Epub 2024 Nov 7. J Parasit Dis. 2025. PMID: 40458498
-
Nitazoxanide refractory cryptosporidiosis complicating Burkitt lymphoma in a child.Trop Parasitol. 2024 Jan-Jun;14(1):50-53. doi: 10.4103/tp.tp_25_23. Epub 2024 Feb 15. Trop Parasitol. 2024. PMID: 38444792 Free PMC article.
-
Use-case scenarios for an anti-Cryptosporidium therapeutic.PLoS Negl Trop Dis. 2021 Mar 11;15(3):e0009057. doi: 10.1371/journal.pntd.0009057. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33705395 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous